Lucentis approved in US for macular oedema following retinal vein occlusion
This article was originally published in Scrip
Executive Summary
The US FDA has approved Roche (Genentech)'s Lucentis (ranibizumab) injection for the treatment of macular oedema following retinal vein occlusion (RVO).